BNP Paribas Arbitrage SA lessened its stake in shares of Agilent Technologies Inc (NYSE:A) by 9.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 499,666 shares of the medical research company’s stock after selling 51,603 shares during the period. BNP Paribas Arbitrage SA’s holdings in Agilent Technologies were worth $33,463,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of A. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in Agilent Technologies by 9.9% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 998,225 shares of the medical research company’s stock valued at $64,086,000 after buying an additional 90,317 shares during the period. Timber Hill LLC purchased a new position in Agilent Technologies in the third quarter worth $1,672,000. Colony Group LLC purchased a new position in Agilent Technologies in the second quarter worth $260,000. Fisher Asset Management LLC acquired a new stake in shares of Agilent Technologies during the third quarter worth $609,000. Finally, Chevy Chase Trust Holdings Inc. lifted its stake in shares of Agilent Technologies by 0.9% during the third quarter. Chevy Chase Trust Holdings Inc. now owns 282,115 shares of the medical research company’s stock worth $18,112,000 after buying an additional 2,599 shares during the period.
A number of research analysts have weighed in on A shares. Zacks Investment Research upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $74.00 price objective for the company in a research report on Tuesday, October 10th. Robert W. Baird reaffirmed a “buy” rating and set a $70.00 price objective on shares of Agilent Technologies in a research note on Friday, October 20th. Morgan Stanley reaffirmed an “overweight” rating on shares of Agilent Technologies in a research note on Tuesday, November 14th. Deutsche Bank set a $75.00 price target on shares of Agilent Technologies and gave the company a “buy” rating in a research note on Tuesday, November 21st. Finally, JPMorgan Chase & Co. increased their price target on shares of Agilent Technologies to $75.00 and gave the company an “overweight” rating in a research note on Tuesday, November 21st. Six investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Agilent Technologies presently has an average rating of “Buy” and a consensus target price of $69.25.
Agilent Technologies (NYSE:A) last posted its earnings results on Monday, November 20th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Agilent Technologies had a net margin of 15.30% and a return on equity of 16.95%. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the company posted $0.59 earnings per share. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. analysts anticipate that Agilent Technologies Inc will post 2.58 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, January 24th. Investors of record on Tuesday, January 2nd were issued a $0.149 dividend. The ex-dividend date of this dividend was Friday, December 29th. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.13. This represents a $0.60 annualized dividend and a yield of 0.82%. Agilent Technologies’s dividend payout ratio is currently 28.71%.
In other Agilent Technologies news, CEO Michael R. Mcmullen sold 22,481 shares of the business’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $70.00, for a total transaction of $1,573,670.00. Following the completion of the sale, the chief executive officer now owns 327,882 shares in the company, valued at $22,951,740. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael R. Mcmullen sold 21,850 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,638,750.00. Following the sale, the chief executive officer now owns 324,687 shares of the company’s stock, valued at approximately $24,351,525. The disclosure for this sale can be found here. In the last quarter, insiders have sold 219,991 shares of company stock valued at $15,468,795.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.